Moderna has inked a deal to move toward producing messenger RNA (mRNA) vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.
The Cambridge, Massachusetts-based company signed a memorandum of understanding and land collaboration agreement on Wednesday to work toward researching, developing and producing mRNA vaccines in China, according to a statement. The U.S.-based developer of an mRNA vaccine for COVID-19 may invest around $1 billion, local media outlet Yicai reported Tuesday, citing sources it didn’t identify.
Moderna declined to comment on the size of its investment.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.